Lansoprazol Qualigen

Lansoprazole, the active ingredient in Lansoprazol Qualigen, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is prescribed for conditions such as gastro‑oesophageal reflux disease, peptic ulcers and other acid‑related disorders in adults.

GNH USA supplies Lansoprazol Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable distribution across multiple regions.

Lansoprazole is used to treat several acid‑related gastrointestinal conditions by decreasing stomach acidity.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH. - Peptic ulcer disease: promotes healing of gastric and duodenal ulcers through acid suppression. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Lansoprazole may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence

Serious or Rare Side Effects: - Severe allergic reactions such as Stevens‑Johnson syndrome - Clostridioides difficile infection - Low magnesium levels (hypomagnesemia) that can cause muscle cramps or cardiac arrhythmia

When prescribing Lansoprazol Qualigen, clinicians should consider several safety and handling measures. - Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Monitor long‑term use: prolonged therapy has been linked to vitamin B12 deficiency and increased fracture risk. - Evaluate infection risk: reduced acidity may predispose to gastrointestinal infections. - Review concomitant medications: potential for altered absorption of drugs requiring an acidic environment. - Store at ambient temperature: keep below 25 °C, retain in the original pack and protect from moisture.

Lansoprazole can affect the pharmacokinetics of other medicines, requiring attention to possible interactions.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (e.g., atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished activation leading to reduced antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: elevated serum levels may occur; check therapeutic range. - Methotrexate (high dose): decreased renal clearance; monitor for toxicity.